Investors and analysts alike are closely monitoring the developments at Abeona. While the resubmission of the BLA may drive short-term interest, the company's history of losses and the effectiveness of its recent talent acquisition strategies will ultimately determine its future in the biotech arena. The next few months will be critical not just for the fate of pz-cel, but for the very survival of Abeona Therapeutics in a notoriously unforgiving market.